Logo image of NLSP

NLS PHARMACEUTICS LTD (NLSP) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:NLSP - CH1384053976 - Common Stock

0.762 USD
+0.02 (+2.97%)
Last: 10/30/2025, 8:00:02 PM
1.08 USD
+0.32 (+41.73%)
After Hours: 10/30/2025, 8:00:02 PM

NLSP Key Statistics, Chart & Performance

Key Statistics
Market Cap4.56M
Revenue(TTM)N/A
Net Income(TTM)-4.06M
Shares5.99M
Float4.82M
52 Week High4.74
52 Week Low0.74
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.93
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2021-01-29
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


NLSP short term performance overview.The bars show the price performance of NLSP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

NLSP long term performance overview.The bars show the price performance of NLSP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of NLSP is 0.762 USD. In the past month the price decreased by -64.06%. In the past year, price decreased by -78.83%.

NLS PHARMACEUTICS LTD / NLSP Daily stock chart

NLSP Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.37 1.01T
JNJ JOHNSON & JOHNSON 19.69 492.44B
MRK MERCK & CO. INC. 12.55 274.34B
PFE PFIZER INC 7.96 144.87B
BMY BRISTOL-MYERS SQUIBB CO 8.52 113.72B
ZTS ZOETIS INC 20.06 56.04B
RPRX ROYALTY PHARMA PLC- CL A 9.77 23.19B
VTRS VIATRIS INC 5.48 14.70B
ELAN ELANCO ANIMAL HEALTH INC 24.45 11.66B
AXSM AXSOME THERAPEUTICS INC N/A 8.54B
BLTE BELITE BIO INC - ADR N/A 5.53B
CRNX CRINETICS PHARMACEUTICALS IN N/A 5.05B

About NLSP

Company Profile

NLSP logo image NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.

Company Info

NLS PHARMACEUTICS LTD

The Circle 6

Zurich ZUERICH CH-6370 CH

CEO: Alexander Zwyer

Employees: 1

NLSP Company Website

NLSP Investor Relations

Phone: 41445122150

NLS PHARMACEUTICS LTD / NLSP FAQ

What does NLSP do?

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company is headquartered in Zurich, Zuerich and currently employs 1 full-time employees. The company went IPO on 2021-01-29. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.


What is the stock price of NLS PHARMACEUTICS LTD today?

The current stock price of NLSP is 0.762 USD. The price increased by 2.97% in the last trading session.


What is the dividend status of NLS PHARMACEUTICS LTD?

NLSP does not pay a dividend.


How is the ChartMill rating for NLS PHARMACEUTICS LTD?

NLSP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


How is the valuation of NLS PHARMACEUTICS LTD (NLSP) based on its PE ratio?

NLS PHARMACEUTICS LTD (NLSP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.93).


What is the ownership structure of NLS PHARMACEUTICS LTD (NLSP)?

You can find the ownership structure of NLS PHARMACEUTICS LTD (NLSP) on the Ownership tab.


NLSP Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

NLSP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NLSP. The financial health of NLSP is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NLSP Financial Highlights

Over the last trailing twelve months NLSP reported a non-GAAP Earnings per Share(EPS) of -2.93. The EPS increased by 77% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -181.68%
ROE -288.47%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%79.24%
Sales Q2Q%N/A
EPS 1Y (TTM)77%
Revenue 1Y (TTM)N/A

NLSP Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y97.19%
Revenue Next YearN/A

NLSP Ownership

Ownership
Inst Owners4.55%
Ins Owners20.51%
Short Float %N/A
Short RatioN/A